Andromeda Increases Warehouse Size by 400% to Scale Abi Robot Production

Why It Matters

The expanded infrastructure enables Andromeda to meet rising demand for empathetic robotics in strained aged‑care systems, positioning the company as a key supplier in both Australian and U.S. markets. Reliable, scalable production is critical for translating AI‑powered companionship into measurable improvements in resident wellbeing and staff efficiency.

Key Takeaways

• New 2,500 sqm warehouse expands production capacity fivefold
• Funding round raised $23 million to accelerate Abi robot rollout
• Abi deployed in 22 Australian aged‑care homes and a US facility
• Waitlist demand drives Andromeda’s disciplined, infrastructure‑first growth strategy

Pulse Analysis

Companion robots are emerging as a strategic response to chronic staffing shortages and social isolation in aged‑care facilities. Andromeda’s Abi, with its multilingual capabilities and emotion‑recognition algorithms, addresses a market projected to exceed $10 billion globally by 2030. By securing $23 million in venture capital and forging partnerships with providers like Mecwacare, the company has validated demand and demonstrated that AI‑driven empathy can be operationalized at scale.

The move to a 2,500‑square‑metre plant is more than a real‑estate upgrade; it resolves a critical bottleneck in robotics manufacturing—space for simultaneous assembly, rigorous testing, and post‑sale servicing. Physical infrastructure directly influences product reliability, especially for autonomous systems that must operate safely around vulnerable residents. Andromeda’s disciplined growth philosophy, which ties capacity expansion to product robustness, mitigates the risk of over‑extension that has plagued many hardware startups.

Looking ahead, Andromeda’s roadmap includes deepening Abi’s behavioral intelligence and expanding into the U.S. market, where regulatory pathways for medical‑assistive robots are becoming clearer. The collaboration with UC Davis’s nursing school adds academic rigor to efficacy studies, potentially unlocking reimbursement models. As the company scales, its ability to maintain high‑quality support will be a differentiator, shaping the broader adoption curve for socially assistive robots in healthcare.